Liver scarring screening for adults with type 2 diabetes
Part of Digestive system, Hormones & metabolism clinical trials.
This study is for people with type 2 diabetes who may have early liver damage (fatty liver) but haven't yet developed severe scarring. It tests a simple screening program to find advanced liver fibrosis early, so it can be treated sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have type 2 diabetes and are being followed by a private-practice diabetes doctor who is part of this study.
- You have French or European health insurance.
- You agree to take part and sign a consent form.
- You have no signs of advanced liver scarring (fibrosis stage F3 or F4) or cirrhosis, and no other cause of liver disease.
- You are not pregnant, breastfeeding, or in a situation that prevents you from understanding or consenting to the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
This study looks at whether a city-hospital partnership can help find liver fibrosis (early scarring of the liver) earlier in people who get a Fibroscan test ordered by their primary care doctor. It is for adults whose Fibroscan result was at least 8 kPa and who had the test between 2023 and 2026.
This study aims to find a simple way to detect liver fibrosis, a condition where the liver becomes scarred, in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. By identifying fibrosis early, it may help prevent more serious liver problems.
Hear when a new Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.